Corcept Therapeutics Incorporated (NASDAQ:CORT) traded up 2.2% on Friday . The company traded as high as $20.77 and last traded at $20.26. 642,343 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 1,238,980 shares. The stock had previously closed at $20.72.

A number of equities research analysts have weighed in on the stock. BidaskClub upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, August 18th. Stifel Nicolaus assumed coverage on shares of Corcept Therapeutics in a report on Thursday, August 31st. They issued a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research cut shares of Corcept Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Piper Jaffray Companies set a $18.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 24th. Finally, Ladenburg Thalmann Financial Services set a $20.00 target price on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating to the company. Corcept Therapeutics currently has a consensus rating of “Buy” and an average target price of $16.17.

The stock has a market cap of $2.31 billion, a PE ratio of 101.34 and a beta of 2.12. The stock has a 50-day moving average of $17.22 and a 200 day moving average of $12.93.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The company had revenue of $35.56 million during the quarter, compared to analysts’ expectations of $31.37 million. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. Corcept Therapeutics’s revenue for the quarter was up 80.3% on a year-over-year basis. During the same period last year, the business earned $0.01 EPS. Analysts forecast that Corcept Therapeutics Incorporated will post $0.42 EPS for the current year.

In other Corcept Therapeutics news, Director David L. Mahoney sold 6,510 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $12.50, for a total transaction of $81,375.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David L. Mahoney sold 6,091 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $12.50, for a total transaction of $76,137.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,601 shares of company stock valued at $532,513. Company insiders own 19.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tanaka Capital Management Inc. lifted its stake in Corcept Therapeutics by 62.6% during the 2nd quarter. Tanaka Capital Management Inc. now owns 139,397 shares of the biotechnology company’s stock valued at $1,645,000 after acquiring an additional 53,692 shares during the period. California State Teachers Retirement System lifted its stake in Corcept Therapeutics by 9.7% during the 2nd quarter. California State Teachers Retirement System now owns 161,438 shares of the biotechnology company’s stock valued at $1,905,000 after acquiring an additional 14,300 shares during the period. 361 Capital LLC acquired a new stake in Corcept Therapeutics during the 2nd quarter valued at approximately $428,000. The Manufacturers Life Insurance Company lifted its stake in Corcept Therapeutics by 201.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 181,414 shares of the biotechnology company’s stock valued at $2,140,000 after acquiring an additional 121,292 shares during the period. Finally, State Street Corp lifted its stake in Corcept Therapeutics by 26.1% during the 2nd quarter. State Street Corp now owns 2,028,013 shares of the biotechnology company’s stock valued at $23,931,000 after acquiring an additional 420,139 shares during the period. Institutional investors and hedge funds own 61.48% of the company’s stock.

WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/corcept-therapeutics-incorporated-cort-trading-2-2-higher/1613555.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.